Profile data is unavailable for this security.
About the company
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
- Revenue in USD (TTM)441.25k
- Net income in USD-2.03m
- Incorporated2022
- Employees3.00
- Location60 Degrees Pharmaceuticals Inc1025 Connecticut Avenue Nw, Suite 1000WASHINGTON 20036United StatesUSA
- Phone+1 (202) 327-5422
- Fax+1 (302) 636-5454
- Websitehttps://60degreespharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evofem Biosciences Inc | 17.71m | 57.36m | 1.16m | 37.00 | 0.0008 | -- | 0.0203 | 0.0657 | -0.4918 | -0.4918 | 0.0297 | -0.7803 | 1.57 | 1.81 | 3.61 | 478,756.80 | 534.21 | -211.64 | -- | -- | 75.75 | -- | 341.16 | -1,031.55 | 0.0841 | -4.50 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| PainReform Ltd | 0.00 | -17.67m | 1.30m | 6.00 | -- | -- | -- | -- | -41.92 | -41.92 | 0.00 | -3.53 | 0.00 | -- | -- | 0.00 | -309.43 | -55.47 | -650.22 | -68.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -6.28 | -- | -- | -- |
| Link Reservations Inc | 0.00 | -480.90k | 1.37m | 0.00 | -- | -- | -- | -- | -46.51 | -46.51 | 0.00 | -13.99 | 0.00 | -- | -- | -- | -246.84 | -- | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -22.69 | -- | -- | -- |
| Mallinckrodt PLC | 1.96bn | 917.30m | 1.60m | 2.80k | -- | -- | 0.0015 | 0.0008 | 20.19 | 20.21 | 79.87 | 52.21 | 0.4641 | 1.68 | 4.83 | 698,892.90 | 21.76 | -12.49 | 25.91 | -15.85 | 33.77 | 35.68 | 46.88 | -44.38 | 1.83 | -0.0138 | 0.6286 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| cbdMD Inc | 20.64m | -23.42m | 1.66m | 52.00 | -- | 0.5472 | -- | 0.0802 | -18.95 | -18.95 | 7.85 | 0.8055 | 0.8817 | 2.01 | 20.35 | 396,856.90 | -82.98 | -38.59 | -112.36 | -41.50 | 63.43 | 63.80 | -94.12 | -87.98 | 0.5172 | -3.89 | 0.3128 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
| Bespoke Extracts Inc | 1.05m | -1.15m | 1.76m | 10.00 | -- | -- | -- | 1.68 | -0.1126 | -0.1126 | 0.1029 | -0.2136 | 2.57 | 15.43 | 20.63 | 104,678.00 | -280.87 | -- | -- | -- | 44.94 | -- | -109.44 | -- | 0.0643 | -35.39 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
| 60 Degrees Pharmaceuticals Inc | 441.25k | -2.03m | 1.77m | 3.00 | 1.01 | -- | -- | 4.02 | 0.9455 | 0.9455 | 0.6336 | 2.98 | 0.0755 | 0.8355 | 2.09 | 147,083.30 | -27.71 | -- | -- | -- | 15.59 | -- | -366.89 | -- | 2.74 | -- | 0.0505 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Altamira Therapeutics Ltd | 59.60k | -224.50k | 1.89m | 10.00 | 0.7351 | 0.2109 | -- | 31.63 | 0.6788 | 0.6788 | 0.0337 | 2.37 | 0.008 | -0.1997 | 3.36 | 5,960.18 | -2.99 | -66.27 | -5.77 | -113.27 | 150.61 | -- | -376.67 | -25,125.90 | 0.4268 | -- | 0.0634 | -- | -- | -- | 89.86 | -- | -- | -- |
| Agentix Corp | 0.00 | -326.32k | 2.00m | -- | -- | -- | -- | -- | -0.0081 | -0.0081 | 0.00 | -0.068 | 0.00 | -- | -- | -- | -131.20 | -- | -- | -- | -- | -- | -- | -- | -- | -16.66 | -- | -- | -- | -- | 57.41 | -- | -- | -- |
| InVitro International | 716.89k | 6.22k | 2.01m | 16.00 | 252.86 | 2.75 | -- | 2.81 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| Procyon Corp | 4.98m | -312.97k | 2.07m | 19.00 | -- | 0.9512 | -- | 0.4146 | -0.0387 | -0.0387 | 0.6138 | 0.2817 | 1.47 | 2.32 | 9.90 | 262,338.40 | -10.08 | 1.19 | -12.70 | 1.44 | 78.07 | 74.40 | -6.84 | 0.8691 | 2.41 | -- | 0.00 | -- | 6.35 | 3.53 | -367.38 | -- | 17.32 | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 2.08m | 40.00 | -- | -- | -- | 0.7511 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| SOHM Inc | -100.00bn | -100.00bn | 2.10m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of Nov 11 2024. Currency figures normalised to 60 Degrees Pharmaceuticals Inc's reporting currency: US Dollar USD
0.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Virtu Americas LLCas of 30 Jun 2024 | 3.76k | 0.20% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.17k | 0.17% |
| UBS Securities LLCas of 30 Jun 2024 | 2.87k | 0.15% |
| HRT Financial LP (US)as of 30 Jun 2024 | 2.40k | 0.13% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 1.43k | 0.08% |
| G1 Execution Services LLCas of 30 Jun 2024 | 1.11k | 0.06% |
| Tower Research Capital LLCas of 30 Jun 2024 | 591.00 | 0.03% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 5.00 | 0.00% |
| Central Bank & Trust Co. (KY Invt Mgmt)as of 30 Sep 2024 | 0.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
